Stoke Therapeutics

STOK

Market cap $1.29B

Overview Fund Activity

23.46 USD

-0.42

1.76%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

23.92

+0.46

1.96%

1 day

-1.76%

5 days

14.33%

1 month

73.39%

3 months

98.48%

6 months

175.35%

Year to date

108.16%

1 year

71.12%

5 years

-32.2%

10 years

-8.25%

About: Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Employees: 128

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

76% more capital invested

Capital invested by funds: $422M [Q1] → $744M (+$322M) [Q2]

47% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 34

44% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 16

33% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]

6% more funds holding

Funds holding: 126 [Q1] → 133 (+7) [Q2]

2.84% more ownership

Funds ownership: 117.2% [Q1] → 120.04% (+2.84%) [Q2]

95% less call options, than puts

Call options by funds: $35K | Put options by funds: $672K

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$22

-6% downside

Avg. target

$25

4% upside

High target

$30

28% upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

Chardan Capital Rudy Li	$24	Buy Maintained	13 Aug 2025
Wedbush Laura Chico	$22	Outperform Maintained	13 Aug 2025
Jefferies Andrew Tsai	$30	Buy Initiated	18 Jul 2025
Needham Joseph Stringer	$22	Buy Reiterated	1 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about STOK published over the past 30 days

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced data from Phase 1/2a and open-label extension (OLE) studies of zorevunersen that support the potential for zorevunersen to be the first disease-modifying medicine for Dravet syndrome. Findings were presented at the 36th International Epil.

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the following upcoming investor conferences: Cantor Global He.

Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced presentations of new clinical data from studies of zorevunersen at the 36th International Epilepsy Congress (IEC), taking place August 30 – September 3, 2025 in Lisbon, Portugal. Zorevunersen, an investigational antisense oligonucleotide,.

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on August 15, 2025, it granted stock options to purchase shares of common stock to Elizabeth Mellen, the Compan.

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Stoke Therapeutics, Inc. (NASDAQ: STOK)

NEW YORK , Aug. 18, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Stoke Therapeutics, Inc. (NASDAQ: STOK) on behalf of the company's shareholders. The investigation seeks to determine whether Stoke Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Stoke Therapeutics, Inc. (NASDAQ: STOK)

Zacks Investment Research

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.46 per share a year ago.

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the second quarter ended June 30, 2025 and provided business updates. “This quarter was defined by strong.

Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced that the first patient has been dosed in the global Phase 3 EMPEROR study of zorevunersen for the treatment of Dravet syndrome. Zorevunersen, an investigational antisense oligonucleotide, has the potential to be the first disease-modifyi.

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that management will host a webcast and conference call for analysts and investors on Tuesday, August 12, 2025, at 4:30 p.m. ET.

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates

Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the Canaccord Genuity 45th Annual Growth Conference on Wednes.

Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

See News Rankings

Charts implemented using Lightweight Charts™